Direct answer: CBD isolate is cannabidiol purified to a crystalline powder, usually sold at 99 percent purity or more, with the plant’s other cannabinoids, terpenes and waxes removed. Purified CBD is also where the strongest human evidence sits: prescription cannabidiol reduced seizures in three rare epilepsies. For pain and exercise recovery, trials have not shown a benefit. In South Africa CBD is a Schedule 4 medicine, with narrow Schedule 0 exemptions.
Last updated:
Key takeaways
- An isolate is a single molecule. A 2025 protocol reached over 99 percent purity through extraction, winterisation, chromatography and crystallisation, with THC negligible rather than guaranteed zero.
- The best human evidence for CBD at all comes from purified CBD: three randomised trials of prescription cannabidiol in Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex.
- For pain, a 2024 review found that 15 of 16 randomised trials using pharmaceutical-grade CBD showed no benefit over placebo. Claims of faster recovery are not supported.
- CBD can raise liver enzymes and interacts with medicines such as clobazam and valproate, and a 2025 FDA-run trial saw liver enzyme rises in healthy adults.
- In South Africa, CBD isolate is a Schedule 4 medicine unless a product fits the narrow Schedule 0 exemptions. General information for adults 18 and over, not medical advice.
What is CBD isolate?
CBD isolate is cannabidiol that has been separated from everything else in the cannabis plant and purified, typically to a white crystalline powder. Products sold as isolate usually state a purity of 99 percent or more. It contains no terpenes or other cannabinoids by design, unlike full-spectrum and broad-spectrum extracts.
The prescribing information for the US prescription medicine Epidiolex describes the pure compound as a white to pale yellow crystalline solid that is insoluble in water and soluble in organic solvents. That is why isolate is usually dissolved in an oil.
Because it is a single, defined molecule, an isolate is easier to measure and standardise than a whole-plant extract. That helps research and manufacture, but it is not evidence of benefit and does not change CBD’s legal status.
How is purified CBD made, and does synthetic CBD exist?
Most CBD isolate starts as industrial hemp. The plant material is heated to convert acidic cannabinoids, extracted with a solvent or supercritical carbon dioxide, winterised to drop out fats and waxes, refined by chromatography and then crystallised. CBD can also be made synthetically in a laboratory without the plant.
A 2025 paper from the Ca’ Foscari University of Venice, published in ACS Agricultural Science and Technology, set out a complete scaled-up procedure from hemp to CBD crystals. The steps were thermal decarboxylation, supercritical carbon dioxide extraction, winterisation of the extract, purification through sequential reverse-phase and silica gel chromatography, and selective crystallisation. The authors reported an overall yield of 52 percent, with purity above 99 percent and a negligible THC content. They noted that robust, scalable protocols for pure CBD are lacking in the literature.
“Negligible” THC is not zero: only testing shows whether a finished product contains any. Refining solvents should also be removed, which is why residual solvent results belong on a certificate of analysis.
Synthetic cannabidiol is made by chemical synthesis rather than extraction, and it is used in research. A 2020 study at the Hebrew University of Jerusalem gave synthetic CBD to 12 healthy male volunteers in three oral forms and found that plasma exposure was significantly higher when it was taken in an oil-based vehicle than as a powder.
Why does the strongest CBD evidence come from purified CBD?
The only randomised trials that have convinced medicines regulators to approve a CBD medicine used a purified, plant-derived cannabidiol: the prescription oral solution sold as Epidiolex in the United States and Epidyolex in Europe. The US label lists seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in patients aged one year and older.
In the 2017 Dravet syndrome trial (New England Journal of Medicine), Devinsky and colleagues randomised 120 children and young adults with drug-resistant seizures to cannabidiol or placebo on top of their usual medicines. Median convulsive seizures per month fell from 12.4 to 5.9 with cannabidiol, against 14.9 to 14.1 with placebo.
The Lennox-Gastaut trial (GWPCARE3, 2018) enrolled 225 patients aged 2 to 55. The median reduction in drop seizures was 41.9 percent and 37.2 percent in the two cannabidiol groups, against 17.2 percent on placebo. Fourteen patients on cannabidiol, about 9 percent, had raised liver aminotransferases.
In tuberous sclerosis complex (GWPCARE6, JAMA Neurology 2021), 224 patients were randomised. Seizures fell by 48.6 and 47.5 percent in the two cannabidiol groups against 26.5 percent on placebo; 18.9 percent on cannabidiol had raised liver transaminases, against none on placebo.
Three limits matter: the trials were funded by the manufacturer, GW Pharmaceuticals; they tested add-on treatment in severe, drug-resistant epilepsy under specialists; and they used a controlled pharmaceutical product, not a retail isolate of uncertain content. Our guide to Epidiolex and how it is accessed in South Africa covers the prescription medicine itself.
| Use or claim | Best evidence found | What it showed |
|---|---|---|
| Dravet syndrome (drug-resistant seizures) | Randomised, placebo-controlled trial, 120 children and young adults (Devinsky, NEJM 2017) | Median convulsive seizures per month fell from 12.4 to 5.9 on CBD, against 14.9 to 14.1 on placebo |
| Lennox-Gastaut syndrome (drop seizures) | Randomised, placebo-controlled trial, 225 patients aged 2 to 55 (Devinsky, NEJM 2018) | Median drop-seizure reduction of 41.9% and 37.2% in the two CBD groups, against 17.2% on placebo |
| Tuberous sclerosis complex (seizures) | Randomised, placebo-controlled trial, 224 patients (Thiele, JAMA Neurology 2021) | Seizure reduction of 48.6% and 47.5% in the two CBD groups, against 26.5% on placebo |
| Chronic neuropathic pain in adults | Cochrane review, 21 trials and 2,187 participants, 5 trials of CBD-dominant medicines (Ates, 2026) | No clear evidence that CBD-dominant medicines produce pain relief of 50% or more |
| Pain of any kind | Review of 16 randomised trials using pharmaceutical-grade CBD across 12 pain conditions (Moore, J Pain 2024) | 15 of the 16 trials showed no benefit of CBD over placebo |
| Exercise performance and recovery | Systematic review, 7 studies in healthy, active people (Bezuglov, Nutrients 2024) | Limited data on any benefit for strength or post-exercise recovery |
What does the evidence show for pain and exercise recovery?
The evidence does not support the claim that purified CBD relieves pain or speeds up recovery. Randomised trials using verified, pharmaceutical-grade CBD have mostly found no difference from placebo for pain, and the few studies in athletes are small and inconclusive. That is the opposite of how many CBD products are marketed.
The most direct review is by Moore and colleagues in the Journal of Pain (2024). They identified 16 randomised trials that used pharmaceutical-supplied CBD with pain as an outcome, covering 12 different pain conditions and oral, topical and under-the-tongue use. Fifteen of the 16 showed no benefit of CBD over placebo. The authors called CBD for pain “expensive, ineffective, and possibly harmful”.
The 2026 update of the Cochrane review of cannabis-based medicines for chronic neuropathic pain in adults, by Ates and colleagues, pooled 21 trials with 2,187 participants. Five trials, with 208 participants, tested CBD-dominant medicines, and there was no clear evidence of pain relief of 50 percent or more against placebo. For exercise, a 2024 systematic review in Nutrients found only seven eligible studies among 901 publications, with limited data on any benefit for strength or recovery.
None of this proves CBD never helps anyone, but promises of faster recovery and pain relief are not supported. Our overview of what the evidence says about cannabis for pain covers THC-containing medicines, which have a different evidence base.
Before you start
CBD is a Schedule 4 medicine in South Africa unless a product fits the narrow Schedule 0 exemptions, so a prescription from a registered doctor is the normal route. This is general information for adults aged 18 and over, not medical advice, and it contains no dosing guidance: speak to your doctor or pharmacist about dosing. Tell them about every medicine you take, especially epilepsy medicines, blood thinners and anything processed by the liver, and do not stop or change any treatment on your own.
What are the safety risks of purified CBD?
The two best-documented risks are raised liver enzymes and interactions with other medicines. Both appear in the prescribing information for pharmaceutical cannabidiol and apply to an isolate because it is the same molecule. Sleepiness and diarrhoea were also more common on CBD in the epilepsy trials.
The US Epidiolex label reports that in controlled trials, the liver enzyme ALT rose above three times the upper limit of normal in 13 percent of patients with Lennox-Gastaut or Dravet syndrome and 12 percent with tuberous sclerosis complex, against 1 percent on placebo. Risk rose sharply with other medicines: the rate was 30 percent in patients also taking both valproate and clobazam, 21 percent with valproate alone, 4 percent with clobazam alone and 3 percent with neither.
The label also states that cannabidiol produces a three-fold increase in blood levels of N-desmethylclobazam, the active metabolite of clobazam, which may increase clobazam side effects. A 2023 review by Herdegen and Cascorbi explains that THC and CBD inhibit the liver enzymes CYP2C and CYP3A4, which clear many common drugs. See our guide to cannabis drug interactions to check before you start.
Liver effects are not confined to epilepsy. In a 2025 randomised trial run by the US Food and Drug Administration (JAMA Internal Medicine), 201 healthy adults took CBD or placebo for 28 days at a dose within the range consumers use. Eight participants on CBD (5.6 percent) and none on placebo had liver enzymes above three times the upper limit of normal, and seven met withdrawal criteria for potential drug-induced liver injury.
Can you trust the label on a CBD product?
Not without independent testing. A CBD product can contain more or less cannabidiol than the label states, and sometimes contains THC it does not declare. For an isolate, the only way to know what is in a specific batch is a certificate of analysis from an independent laboratory that matches the batch number on the pack.
The best-known study is by Bonn-Miller and colleagues in JAMA (2017). They bought 84 CBD extracts from 31 companies online and tested them. Only 30.95 percent were accurately labelled for CBD; 42.85 percent contained more CBD than stated and 26.19 percent contained less. THC was detected in 18 of the 84 samples, at up to 6.43 mg/mL. These were CBD extracts in general, not isolates alone, but a purity claim on a label is still not a test result.
A useful certificate of analysis names the laboratory and batch, gives measured CBD per unit, reports THC with the detection limit stated, and covers residual solvents, heavy metals and microbes. “THC not detected” only means below that limit. Our guide on how CBD is regulated in South Africa explains how registered medicines differ from retail products.
How is an isolate regulated in South Africa?
In South Africa, cannabidiol is listed in Schedule 4 of the Medicines and Related Substances Act schedules, which makes it a prescription medicine. Only two narrow categories drop to Schedule 0: certain low-dose complementary medicines, and some processed foods containing only naturally occurring traces. Purity does not change the schedule.
SAHPRA’s communication to industry on Government Notice 586 (Government Gazette 43347, 22 May 2020) sets out the exemptions. A complementary medicine falls to Schedule 0 if it contains no more than 600 mg of cannabidiol per sales pack, provides a maximum daily dose of 20 mg, and makes only a general health enhancement, health maintenance or relief of minor symptoms (low-risk) claim. Processed products made from cannabis raw plant material intended for ingestion fall to Schedule 0 at 0,0075 percent CBD or less, but only where the product contains the naturally occurring quantity of cannabinoids found in the source material.
Those figures are regulatory ceilings, not dosing advice. The wording suggests a pain or recovery claim is not a low-risk claim, and that cannabidiol added to a food is arguably not a naturally occurring quantity. Whether a specific product is lawful is a question for a legal practitioner. The same notice lists (-)-trans-delta-9-tetrahydrocannabinol in Schedule 6, with an exception for processed products containing 0,001 percent THC or less.
How does an isolate compare with full-spectrum and broad-spectrum CBD?
An isolate is cannabidiol alone. A full-spectrum extract keeps the plant’s other cannabinoids, including some THC, and its terpenes. A broad-spectrum extract keeps many of those compounds but has the THC reduced or removed. Legally, the CBD in all three is scheduled the same way.
Claims that whole-plant blends work better, the so-called entourage effect, are not settled by controlled human trials. Our guides to full-spectrum CBD and broad-spectrum CBD cover those product types separately.
How Professor Green fits into the process
Professor Green is a South African medical cannabis access platform and a marketing affiliate of the Dr Green network, which holds the medical cannabis licences. Professor Green does not itself sell, handle or ship cannabis. Products are sold and fulfilled by the licensed operator.
A registered doctor assesses you, reviews your other medicines and decides whether a cannabinoid medicine is appropriate, applying to SAHPRA under section 21 where a product is unregistered. A registered pharmacy dispenses and counsels you, and the licensed operator supplies.
Professor Green performs none of those regulated acts: it does not assess, prescribe, advise on doses, dispense or decide eligibility. Registering is a first step only and does not guarantee eligibility, a prescription, a SAHPRA authorisation or supply. If you notice a side effect, tell your prescriber and pharmacist.
If you want to know whether a purified CBD medicine makes sense alongside your other medicines, the answer starts with a doctor, not a label. Register for Professor Green store access to begin the doctor-led route. A registered doctor still assesses you, and registration does not guarantee eligibility, a prescription or supply.
The bottom line on CBD isolate
Purified cannabidiol has the strongest evidence of any CBD form, but only for three rare, severe epilepsies under specialist care. For pain and exercise recovery, controlled trials have not shown a benefit, and liver effects and interactions are real enough to need a doctor’s oversight.
If you are weighing CBD isolate, the useful questions are what exactly is in the batch, how it fits with your other medicines, and which legal route applies.
Frequently asked questions
What is CBD isolate?
It is cannabidiol purified to a crystalline powder, usually sold at 99 percent purity or more, with the plant’s other cannabinoids, terpenes and waxes removed.
Does an isolate contain any THC?
It should contain very little, but purification reduces THC to negligible levels rather than guaranteeing zero. A 2017 JAMA study found THC in 18 of 84 CBD extracts bought online. Only a batch certificate of analysis shows the result, and “not detected” means below the laboratory’s limit.
Does purified CBD help with pain or muscle recovery?
The evidence says no so far. A 2024 review found 15 of 16 randomised trials of pharmaceutical-grade CBD showed no benefit over placebo for pain, and a 2024 systematic review found limited data on post-exercise recovery.
Can CBD affect the liver?
Yes. The Epidiolex label reports ALT rises above three times normal in 12 to 13 percent of trial patients, mostly with valproate. A 2025 FDA-run trial found such rises in 5.6 percent of healthy adults on CBD and none on placebo.
Is CBD isolate legal in South Africa?
CBD is a Schedule 4 medicine, so it normally needs a prescription. Only complementary medicines within 600 mg per pack, 20 mg per day and a low-risk claim, or certain foods with naturally occurring traces, fall to Schedule 0.
What dose of isolate should I take?
That is a clinical decision. This page gives no dosing figures on purpose, and the Schedule 0 limits are legal ceilings, not recommendations. Speak to your doctor or pharmacist about dosing.
Sources and references
- SAHPRA, Communication to industry: scheduling status of THC and CBD (GN 586, GG 43347, 22 May 2020)
- US FDA, Epidiolex (cannabidiol) oral solution prescribing information, NDA 210365, revised 02/2022
- Devinsky O et al, Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome, N Engl J Med 2017
- Devinsky O et al, Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome, N Engl J Med 2018
- Thiele EA et al, Add-on cannabidiol for drug-resistant seizures in tuberous sclerosis complex, JAMA Neurol 2021
- Moore A et al, Cannabidiol (CBD) products for pain: ineffective, expensive, and with potential harms, J Pain 2024
- Ates G et al, Cannabis-based medicines for chronic neuropathic pain in adults, Cochrane Database Syst Rev 2026
- Bezuglov E et al, Cannabidiol on performance and post-load recovery: a systematic review, Nutrients 2024
- Florian J et al, Cannabidiol and liver enzyme level elevations in healthy adults, JAMA Intern Med 2025
- Herdegen T, Cascorbi I, Drug interactions of THC and CBD in cannabinoid drugs, Dtsch Arztebl Int 2023
- Bonn-Miller MO et al, Labeling accuracy of cannabidiol extracts sold online, JAMA 2017
- Calmanti R et al, From hemp to CBD crystals: extraction, isolation and purification of cannabidiol, ACS Agric Sci Technol 2025
- Izgelov D et al, Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers, Eur J Pharm Biopharm 2020
Figures are taken from the sources cited above, most of them from outside South Africa, and the legal position is South African law as at 18 September 2026. General information for adults aged 18 and over, not medical advice, with no dosing recommendations; it does not replace a registered doctor, pharmacist or legal practitioner.
Considering CBD isolate? Start with a doctor
A purified CBD product still has to fit your health, your other medicines and South African scheduling rules. Professor Green connects you to the doctor-led route: a registered doctor assesses and prescribes, a pharmacy dispenses, and a licensed operator supplies. Registration does not guarantee eligibility or supply.
Register for Store Access

